GURU.Markets stock price, segment price, and overall market index valuation
The company's share price MaxCyte Inc.
MaxCyte offers a unique electroporation technology that delivers genes into cells. Its stock price reflects a bet that its technology will become the standard in cell and gene therapy. The price chart reflects licensing agreements with leading biotech companies.
Share prices of companies in the market segment - Diagnostic medical equipment
MaxCyte, Inc. provides a cell engineering technology platform that enables drug developers to quickly and efficiently modify cells. We classify it as "Diagnostic Medical Equipment," although it is a tool for therapeutic development. The chart below shows the dynamics of this biotech infrastructure sector.
Broad Market Index - GURU.Markets
MaxCyte is a company that provides a cell engineering platform, enabling drug developers to efficiently deliver molecules into cells. As a component of the GURU.Markets index, it is a key partner for the pharmaceutical industry. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
MXCT - Daily change in the company's share price MaxCyte Inc.
Change_co for MaxCyte, a cell engineering company, measures its volatility. It reflects its sensitivity to the success of its partners in the pharmaceutical industry. This metric is important for analyzing biotech service companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Diagnostic medical equipment
MaxCyte, Inc. is a company providing cell engineering technologies. This chart illustrates the high volatility of the life sciences sector. Comparing it to MXCT, a key supplier to pharmaceutical companies, helps assess its stability.
Daily change in the price of a broad market stock, index - GURU.Markets
MaxCyte provides a cell engineering platform used by many biotech companies. It's a "picks and shovels" seller during the cell therapy gold rush. The company's stock reflects the health and investment in the entire industry, serving as an important indicator.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization MaxCyte Inc.
For MaxCyte, Inc., year-over-year performance is a reflection of its role as an "infrastructure" player in cell therapy. Its 12-month market cap growth reflects the growing number of pharmaceutical companies licensing its electroporation platform, a key tool for creating gene-modified cell-based therapies.
Annual dynamics of market capitalization of the market segment - Diagnostic medical equipment
MaxCyte, Inc. provides a unique cell engineering platform used by leading pharmaceutical companies to develop cell therapies. Its technology is a "shovel in the gold rush." This chart shows how its key role in this ecosystem and its licensing model are driving its accelerated growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
MaxCyte, with its cell engineering platform, is a gold mine for biotech. Demand for its technology is not dependent on the economy, but is driven by pharmaceutical companies' R&D budgets. The company's stock price reflects the long-term trend toward cell therapy, making it a defensive technology bet.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization MaxCyte Inc.
MaxCyte, Inc. (Diagnostic Medical Equipment) provides a cell engineering platform. Its Perf_Month_Co shows how operating cycles for licensing agreements with biotech and pharmaceutical companies impact mid-term value. The graph reflects the pace of adoption of their technology.
Monthly dynamics of market capitalization of the market segment - Diagnostic medical equipment
This chart illustrates the dynamics of the biotech sector, particularly cell therapy tools. For MaxCyte, a key supplier, this is the backdrop. Its movements demonstrate how the growth of the entire cell and gene therapy industry is driving demand for its technology.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
MaxCyte provides a cell engineering platform used by many pharmaceutical and biotech companies to develop cell therapies. It's a "pick and shovel" model. A full-market chart allows you to assess how MaxCyte's stock, as a provider of critical technologies, moves in sync with overall sentiment in the healthcare sector.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization MaxCyte Inc.
MaxCyte, Inc. provides electroporation technology that delivers molecules into cells, which is critical for developing cell therapies. Its weekly stock price is driven by the performance of its clients—pharmaceutical and biotech companies.
Weekly dynamics of market capitalization of the market segment - Diagnostic medical equipment
MaxCyte provides a cell engineering platform used by other biotech and pharmaceutical companies. It's a "gold rush shovel provider." Compare its performance to the sector to understand whether its business model is more sustainable than that of its drug development clients.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
MaxCyte is a "shovel supplier" for cell therapy. Its business model may be more stable than that of its drug developer clients. The chart will show whether its stock is truly less volatile than the market due to its key role in the industry.
Market capitalization of the company, segment and market as a whole
MXCT - Market capitalization of the company MaxCyte Inc.
MaxCyte's market capitalization reflects its unique position as a provider of technology that delivers molecules into cells for cell therapy development. Its chart shows how investors view it not as a drug developer, but as a supplier of "picks and shovels" for the entire gene and cell therapy industry.
MXCT - Share of the company's market capitalization MaxCyte Inc. within the market segment - Diagnostic medical equipment
MaxCyte is a leading company providing electroporation technology, which enables the delivery of various molecules into cells. Its dominant market share makes it a key partner for many cell therapists. The graph shows how its technology has become a vital tool for 21st-century drug discovery.
Market capitalization of the market segment - Diagnostic medical equipment
Here's a chart showing the market capitalization of the biotech sector. MaxCyte doesn't develop drugs, but rather provides a critical technology—an electroporation system that allows for the introduction of genes into cells. The growth of this market would be impossible without such "tool" companies. MaxCyte is a key partner for the entire cell therapy industry.
Market capitalization of all companies included in a broad market index - GURU.Markets
MaxCyte provides a cell engineering platform used by pharmaceutical companies to develop cell therapies. Its market capitalization is based on its role as a key technology provider. The chart below shows the economic weight of companies creating biotech tools.
Book value capitalization of the company, segment and market as a whole
MXCT - Book value capitalization of the company MaxCyte Inc.
MaxCyte's foundation is its unique Flow Electroporation® platform for cell engineering, which it licenses to biotech and pharmaceutical companies. The chart tells the story of a company providing "shovels" in the cell therapy gold rush: its material base grows as more companies adopt its technology.
MXCT - Share of the company's book capitalization MaxCyte Inc. within the market segment - Diagnostic medical equipment
MaxCyte provides a cell engineering platform. The chart shows its share of real assets. These are its manufacturing facilities, where electroporation machines, a key tool for creating cell and gene therapies, are assembled.
Market segment balance sheet capitalization - Diagnostic medical equipment
MaxCyte produces cell engineering equipment, making its business capital-intensive. The chart below shows the total value of its assets in the medical equipment sector, providing a backdrop for assessing its manufacturing base.
Book value of all companies included in the broad market index - GURU.Markets
MaxCyte provides cell engineering technology used by many biopharmaceutical companies. The company's assets include its devices and patents. Its stake in BCap_All represents the physical value of its technology, which has become a "shovel in the cell therapy gold rush."
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - MaxCyte Inc.
MaxCyte is a company whose technology is critical to cell therapy. Its high premium stems from the valuation of its unique electroporation devices, which are used by nearly all leading gene therapy companies.
Market to book capitalization ratio in a market segment - Diagnostic medical equipment
MaxCyte provides a cell engineering platform used by other biopharmaceutical companies. Its value lies in its technology and its royalty-free business model. The chart shows the high premium the market is paying for its role as a "shovel provider" in the cell therapy gold rush.
Market to book capitalization ratio for the market as a whole
MaxCyte provides technology that delivers molecules into cells. This is a critical tool for companies developing cell and gene therapies. This chart shows the market premium for the "shovels and picks" of the biotech revolution—the technologies that everyone uses.
Debts of the company, segment and market as a whole
MXCT - Company debts MaxCyte Inc.
MaxCyte, Inc. provides cell engineering technology used by many biotech companies. Its leveraged strategy is aimed at expanding the application of its Flow Electroporation® platform. Capital is used for R&D and to support partners who pay MaxCyte for using the technology in their clinical development.
Market segment debts - Diagnostic medical equipment
MaxCyte provides a technology platform that enables cell therapy developers to efficiently deliver genes into cells. This is a critical tool for the entire industry. This chart shows how the company is funding the expansion of its technology, becoming an integral part of next-generation drug development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio MaxCyte Inc.
MaxCyte provides a cell engineering platform used by other biopharmaceutical companies. Its business model may be less risky than that of drug developers. This chart shows its debt load. Low debt may indicate stable income from equipment sales and licensing, while high debt indicates investments in expansion.
Market segment debt to market segment book capitalization - Diagnostic medical equipment
MaxCyte, Inc. provides a cell engineering platform used by biotech companies to develop cell therapies. The chart shows debt trends in their sector. It helps assess the sustainability of the company's technology-licensing business model and how it manages its capital to support its growing number of partners.
Debt to book value of all companies in the market
MaxCyte, Inc. provides a cell engineering technology platform used by many biopharmaceutical companies. Its business model is based on equipment sales and licensing. This graph of the market's total debt load allows us to assess MaxCyte's reliance on debt. The company likely has stable revenue and can finance growth with its own funds while maintaining low debt.
P/E of the company, segment and market as a whole
P/E - MaxCyte Inc.
MaxCyte provides cell engineering technology used by pharmaceutical companies to develop cell therapies. This chart shows how the market values its "pick-and-shovel" model in biotech. Its valuation depends not on the success of a single drug, but on the growth of the entire cell therapy industry, making it less risky.
P/E of the market segment - Diagnostic medical equipment
This industry chart for biotech tool companies is a benchmark for MaxCyte. It shows the high valuations investors assign to this sector. Comparisons help understand whether MaxCyte's electroporation technology, which is key to cell therapy development, is valued more or less highly than that of other providers.
P/E of the market as a whole
MaxCyte provides a technology (electroporation) for delivering molecules into cells, which is used by other companies to develop cell therapies. MaxCyte is a "shovel supplier" in the genetic engineering gold rush. This biotech sentiment chart shows how investors view this business model: whether they prefer risky therapeutic companies or their more stable suppliers.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company MaxCyte Inc.
MaxCyte provides a cell engineering technology platform used by biotech companies to develop cell therapies. This graph reflects the expected growth of the entire gene and cell medicine industry. This estimate depends not on the success of a single drug, but on the widespread adoption of its technology by companies working in this cutting-edge field.
%20P%2FE%20MaxCyte%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-MaxCyte-Inc.&v=1772534916509 "Chart of the company's future (projected) P/E MaxCyte Inc.")
Future (projected) P/E of the market segment - Diagnostic medical equipment
MaxCyte is a leading cell engineering company whose platform enables rapid and efficient delivery of molecules into cells. This chart reflects investor expectations for the company's profitability relative to the sector. It provides insight into how the market views its key role in the development of cell and gene therapies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Diagnostic-medical-equipment&v=1772534916512 "Future (projected) P/E graph of the market segment - Diagnostic medical equipment")
Future (projected) P/E of the market as a whole
MaxCyte provides a cell engineering platform used by pharmaceutical and biotech companies to develop cell therapies. This chart, reflecting sentiment in the biotech sector, is key for MXCT. Growing investment in gene and cell therapies directly increases demand for their technology, which is essential for developing new drugs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772534916532 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit MaxCyte Inc.
MaxCyte, Inc. provides cell engineering technology (electroporation) used by pharmaceutical companies to develop cell therapies. The company's business model includes equipment sales and licensing fees. This chart shows the financial performance of a key technology partner for the entire gene and cell therapy industry.
Profit of companies in the market segment - Diagnostic medical equipment
MaxCyte provides a cell engineering platform used by biopharmaceutical companies to develop cell therapies. This chart shows profitability in the medical device sector. For MXCT, this reflects the growth of the entire cell and gene therapy industry. They are the "picks and shovels" in this gold rush.
Overall market profit
MaxCyte provides a unique cell engineering platform that enables drug developers to quickly and efficiently modify cells. The company's technology is used by many biotech companies. MaxCyte's growth is driven by activity in the cell and gene therapy sector. This gross profit chart reflects the overall state of the pharmaceutical market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company MaxCyte Inc.
MaxCyte provides a proprietary cell engineering platform used by many biotech companies to develop their cell therapies. The revenue forecast presented here reflects growth expectations for the entire cell and gene therapy industry. It's a kind of "shovel and pickaxe" for this revolutionary sector.
%20profit%20of%20the%20company%20MaxCyte%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-MaxCyte-Inc.&v=1772534916597 "Graph of future (projected) profit of the company MaxCyte Inc.")
Future (predicted) profit of companies in the market segment - Diagnostic medical equipment
MaxCyte provides a cell engineering platform used by pharmaceutical companies to develop cell therapies. Its business model is akin to selling shovels during a gold rush. The outlook for this sector depends on overall progress in gene and cell therapy. This chart reflects analysts' expectations for the future of this revolutionary industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Diagnostic-medical-equipment&v=1772534916616 "Graph of future (predicted) profits of companies in a market segment - Diagnostic medical equipment")
Future (predicted) profit of the market as a whole
MaxCyte provides a cell engineering platform used by biotech companies to develop new drugs. Its business is the "shovel and pickaxe" in the cell therapy gold rush. This chart, along with its profit projections, illustrates the overall investment climate in biotech, which drives the activity of MaxCyte's clients.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772534916646 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - MaxCyte Inc.
MaxCyte provides a technology platform that enables cell therapy developers to efficiently deliver genes into cells. This chart shows how the market values its business model, which relies on sales of equipment, consumables, and royalties. Its technology is critical to the growing gene therapy industry.
P/S market segment - Diagnostic medical equipment
MaxCyte provides electroporation technology that enables the rapid and efficient delivery of various molecules into cells. This technology is key to the development of cell therapies. This graph reflects the average revenue estimate for the sector, helping to understand the premium the market is paying for MaxCyte's unique and in-demand technology.
P/S of the market as a whole
MaxCyte provides a cell engineering platform that enables pharmaceutical companies to quickly and efficiently develop cell therapies. The company's business model includes equipment sales and licensing fees. This chart provides a general market backdrop for assessing investor sentiment toward companies providing key technologies to the pharmaceutical industry.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company MaxCyte Inc.
MaxCyte, Inc. provides a cell engineering platform that enables drug developers to quickly and efficiently modify cells. This chart shows how investors estimate the company's future revenue, reflecting its key role in the growing cell and gene therapy industry.
%20P%2FS%20MaxCyte%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-MaxCyte-Inc.&v=1772534916790 "The graph of the company's future (projected) P/S MaxCyte Inc.")
Future (projected) P/S of the market segment - Diagnostic medical equipment
MaxCyte, Inc. provides a cell engineering technology platform that enables drug developers to quickly and efficiently modify cells. Its technology is used by many biopharmaceutical companies. This chart shows how investors view its role as a key supplier of tools for the growing cell therapy industry.
%20P%2FS%20market%20segment%20graph%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Diagnostic-medical-equipment&v=1772534916827 "Future (projected) P/S market segment graph - Diagnostic medical equipment")
Future (projected) P/S of the market as a whole
MaxCyte provides a cell engineering platform used by biotech companies to develop cell therapies. Their business is the "shovels and picks" in the gene therapy gold rush. This market optimism is significant. It ensures an influx of capital into biotech, allowing their clients to launch more research programs using the MaxCyte platform.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772534916855 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales MaxCyte Inc.
MaxCyte provides a unique technology (electroporation) that enables cell therapy developers to quickly and efficiently modify cells. This chart shows revenue from sales of equipment, consumables, and licenses. Revenue growth reflects MaxCyte's status as a key supplier to the rapidly growing cell and gene therapy industry.
Sales of companies in the market segment - Diagnostic medical equipment
MaxCyte provides a technology platform that is critical to the cell therapy industry. Their system enables the rapid and efficient introduction of genes or other molecules into cells to create living drugs. Their revenue is split between equipment sales and leasing, as well as royalties from companies using their technology.
Overall market sales
MaxCyte provides a cell engineering technology platform that enables pharmaceutical companies to quickly and efficiently modify cells to create new treatments (cell and gene therapies). This total revenue chart includes the healthcare sector, where MXCT serves as a key technology partner for numerous innovative companies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company MaxCyte Inc.
MaxCyte provides electroporation technology that enables the introduction of various molecules (such as genes) into cells. This technology is key to the development of cell and gene therapies. This graph reflects the expected growth of this sector, as MaxCyte generates revenue from equipment sales and licensing.
%20sales%20of%20the%20company%20MaxCyte%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-MaxCyte-Inc.&v=1772534917141 "Schedule of future (projected) sales of the company MaxCyte Inc.")
Future (projected) sales of companies in the market segment - Diagnostic medical equipment
MaxCyte offers unique electroporation technology that enables the delivery of molecules into cells, a key step in developing cell therapies. This chart shows market forecasts for gene and cell therapy tools. Demand for MaxCyte's technology is growing alongside the number of companies developing these revolutionary drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Diagnostic-medical-equipment&v=1772534917201 "Schedule of future (projected) sales of companies in the market segment - Diagnostic medical equipment")
Future (projected) sales of the market as a whole
MaxCyte, Inc., a company providing cell engineering technologies, sees this chart as a barometer for the entire cell and gene therapy industry. Rising overall economic forecasts provide funding for hundreds of biotech companies, many of which use the MaxCyte platform to develop their innovative drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772534917233 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality MaxCyte Inc.
MaxCyte, Inc. provides a cell engineering platform used by biotech companies for drug development. Its business model combines equipment sales and licensing fees. This chart shows how successfully the company monetizes its core technology, converting revenue from partnerships and sales into sustainable profits.
Market segment marginality - Diagnostic medical equipment
MaxCyte provides a cell engineering technology platform used by pharmaceutical companies to develop cell therapies. This metric reflects the value of its technology. This high score indicates that its platform is an industry standard and demonstrates a stable revenue stream from licensing.
Market marginality as a whole
MaxCyte provides a cell engineering technology platform used by many biotech companies. Its business is like a pickaxe in the cell therapy gold rush. This overall profitability chart doesn't reflect the exponential growth in its specific scientific niche.
Employees in the company, segment and market as a whole
Number of employees in the company MaxCyte Inc.
MaxCyte provides a unique technology (electroporation) that enables cell therapy developers to quickly and efficiently deliver genes into cells. This graph shows the team, which provides its equipment and expertise to dozens of pharmaceutical companies, playing a vital role as a technological partner in the cell and gene therapy revolution.
Share of the company's employees MaxCyte Inc. within the market segment - Diagnostic medical equipment
MaxCyte, Inc. provides unique electroporation technology that enables the delivery of molecules into cells, a key step in developing cell therapies. As a technology partner for many biopharmaceutical companies, it requires a team of engineers and scientists. This graph illustrates its fundamental role in the industry.
Number of employees in the market segment - Diagnostic medical equipment
MaxCyte provides a technology (electroporation) that enables the safe and effective delivery of various molecules (such as genes) into cells. This platform is used by many companies developing cell and gene therapies. This graph shows a team that isn't creating drugs, but rather a critical tool for the entire industry.
Number of employees in the market as a whole
MaxCyte, Inc. provides cell engineering technologies that enable drug developers to create new treatments. This overall employment chart reflects the health of the biotech and pharmaceutical industries. Growth in these sectors means an increasing number of research programs, many of which rely on MaxCyte's platform to develop their cell therapies.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company MaxCyte Inc. (MXCT)
MaxCyte, Inc. provides cell engineering technology used by other pharmaceutical companies. This chart represents their "shovel salesman" model. Their high market capitalization per employee reflects their key role in the industry. Their technology is the foundation for dozens of other developments, creating enormous value with a relatively small team.
%20of%20the%20company%20MaxCyte%20Inc.%20(MXCT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-MaxCyte-Inc.-MXCT&v=1772534917465 "Chart of market capitalization per employee (in thousands of dollars) of the company MaxCyte Inc. (MXCT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Diagnostic medical equipment
MaxCyte, Inc. provides a cell engineering platform used by pharmaceutical and biotech companies for drug development. Its business model is based on technology, not a large staff. This chart shows how highly the market values its leading technology platform per employee.
%20by%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Diagnostic-medical-equipment&v=1772534917511 "Market capitalization per employee (in thousands of dollars) by market segment - Diagnostic medical equipment")
Market capitalization per employee (in thousands of dollars) for the overall market
MaxCyte provides electroporation technology for cell engineering, which is used by many pharmaceutical and biotech companies. This metric reflects its unique "instrument and consumables" business model and demonstrates that its technology is critical to the entire cell therapy industry.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772534917550 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company MaxCyte Inc. (MXCT)
MaxCyte is a company whose technology (electroporation) enables gene delivery into cells. This is critical for cell therapy. This graph illustrates their "razor and blades" model. They sell or lease their equipment and then receive royalties and payments from biotech companies that use their technology in their R&D and manufacturing.
%20Chart%20MaxCyte%20Inc.%20(MXCT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-MaxCyte-Inc.-MXCT&v=1772534917603 "Company Profit Per Employee (in thousands of dollars) Chart MaxCyte Inc. (MXCT)")
Profit per employee (in thousands of dollars) in the market segment - Diagnostic medical equipment
MaxCyte (MXCT) is a company that provides a technology platform (Flow Electroporation) for cell engineering. Their equipment is used by biotech companies (including Caribou) to create CAR-T and other cell therapies. This chart shows the industry benchmark. MaxCyte is the "pick and shovel" of biotech; it reflects how effectively they sell and lease their critical tools to R&D companies.
%20in%20the%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Diagnostic-medical-equipment&v=1772534917667 "Chart of profit per employee (in thousands of dollars) in the market segment - Diagnostic medical equipment")
Profit per employee (in thousands of dollars) for the market as a whole
MaxCyte is a company whose technology (Flow Electroporation) is key to the cell therapy industry. They don't make drugs, but rather sell devices and licenses (a "pick-and-shovel" model) that enable others (Novartis, Kite) to create CAR-T therapies. This chart demonstrates the high scalability of their IP business, generating high-margin income from royalties and consumables.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772534917725 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee MaxCyte Inc. (MXCT)
MaxCyte provides a cell engineering platform used by biotech companies to develop their therapies. This graph illustrates a "pick and shovel" model. High revenue per employee is generated by selling and licensing its technology to other companies, allowing it to profit from the success of the entire cell therapy industry.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-MaxCyte-Inc.-MXCT&v=1772534917745 "Sales chart per company employee MaxCyte Inc. (MXCT)")
Sales per employee in the market segment - Diagnostic medical equipment
MaxCyte (MXCT) provides a platform (machines and consumables) for cell engineering, which is used by biotech companies (like Caribou) for their developments. It's a "pick and shovel" model. This chart shows how effective their model (R&D, equipment sales) is in generating revenue per employee compared to other medical device providers.
Sales per employee for the market as a whole
MaxCyte is a "shovel maker" for genetic engineering. They produce machines (electroporation systems) that allow biotech companies to "inject" genes into cells (for CAR-T). It's a "razor and blades" model (machines and consumables). This graph shows how their R&D team generates recurring revenue.
Short shares by company, segment and market as a whole
Shares shorted by company MaxCyte Inc. (MXCT)
MaxCyte (MXCT) provides a cell engineering platform (Flow Electroporation) used by biotech companies to develop their cell therapies (e.g., CAR-T). This chart measures bearish bets. The rise in shorts may reflect concerns that their clients (biotech startups) are cutting R&D budgets or that MaxCyte's technology will face competition.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-MaxCyte-Inc.-MXCT&v=1772534917882 "Short Shares Chart for the Company MaxCyte Inc. (MXCT)")
Shares shorted by market segment - Diagnostic medical equipment
MaxCyte (MXCT) provides a cell engineering platform (Flow Electroporation) used by biotech companies to develop cell therapies. This chart illustrates the general skepticism in the biotech sector. It reflects the sector's reliance on R&D funding, which drives demand for MaxCyte's equipment.
Shares shorted by the overall market
MaxCyte (MXCT) sells cell engineering equipment. It's a key player in the biotech gold rush. But its clients are R&D companies. When this chart shows rising fear, it signals a "venture winter." This means MaxCyte's clients (small biotechs) are freezing their R&D and stopping buying its expensive equipment.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator MaxCyte Inc. (MXCT)
MaxCyte is the "pick and shovel" of gene therapy. They don't create drugs, but rather manufacture "machines" (Flow Electroporation) that allow pharmaceutical companies to introduce genes into cells. This chart measures investor confidence in this enabling technology, showing peaks of hype (overbought) and valleys (oversold).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-MaxCyte-Inc.-MXCT&v=1772534918048 "RSI 14 indicator chart for the company's stock MaxCyte Inc. (MXCT)")
RSI 14 Market Segment - Diagnostic medical equipment
MaxCyte is a key supplier to the cell therapy industry. Their Flow Electroporation technology is a tool used by biotech companies to deliver genes into cells to create drugs. This chart measures the overall momentum in the medical device sector. It helps assess whether this entire "auxiliary" biotech sector is overheated.
RSI 14 for the overall market
MaxCyte (MXCT) is a "supplier" for biotechs (cell therapy). This chart shows the "health" of its clients. In the euphoria, biotechs easily attract capital and actively pursue R&D, buying up MXCT equipment. In a panic, R&D funding dries up, biotechs "freeze" research, and demand for equipment falls.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MXCT (MaxCyte Inc.)
MaxCyte (MXCT) provides a technology platform (Flow Electroporation) used by pharmaceutical companies to develop cell therapies. They are the "spade" of the gene therapy world. This chart shows the average 12-month forecast, reflecting analyst expectations for growth in licensing deals and consumable sales.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MXCT-MaxCyte-Inc.&v=1772534918345 "A chart showing analyst consensus forecasts for the expected stock price. MXCT (MaxCyte Inc.)")
The difference between the consensus estimate and the actual stock price MXCT (MaxCyte Inc.)
MaxCyte is a weaponizing company for cell therapy. Their ExPERT platform is used by dozens of pharmaceutical companies to "download" genes into cells. This chart shows the growth potential analysts see. The gap reflects their belief that MaxCyte will earn royalties from future cell therapy blockbusters.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MXCT-MaxCyte-Inc.&v=1772534918493 "A chart showing the difference between the consensus forecast and the actual stock price. MXCT (MaxCyte Inc.)")
Analyst consensus forecast for stock prices by market segment - Diagnostic medical equipment
MaxCyte is a "weapons supplier" for cell therapy. The company produces an "electroporation" system that allows pharmaceutical companies to "inject" genes into cells to create drugs. This chart shows general expectations for the medical device sector. It reflects whether experts believe the cell therapy market as a whole will grow.
Analysts' consensus forecast for the overall market share price
MaxCyte is a gene therapy "tool" company. They don't treat cancer, but rather produce "guns" (electroporation systems) that allow biotechs (like Caribou) to "load" drugs into cells. This chart shows the overall market sentiment. For MaxCyte, a "shovel supplier," it's important to understand how these expectations (risk appetite) influence R&D budgets across the biotech industry. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index MaxCyte Inc.
MaxCyte is a technology provider for gene therapy. Their signature technology is flow-through electroporation: machines that allow pharmaceutical companies (their clients) to quickly and efficiently load genes (DNA/RNA) into patients' cells. This graph is a valuation of their razor and blades. It reflects their revenue from razor sales (the machines) and, more importantly, their growing royalties from blades (their partners' successful therapies).
AKIMA Market Segment Index - Diagnostic medical equipment
MaxCyte is a leading cell engineering company. Its Flow Electroporation™ platform is used by biotech companies to develop cell therapies. MaxCyte is a leading provider of biotech products. This chart shows the average index for the diagnostics sector. It allows you to assess how MaxCyte's technology outperforms the industry average.
The AKIM Index for the overall market
MaxCyte is a provider of cell engineering technologies (electroporation) for the biotech industry. It's a "pick and shovels" for cell therapy. This chart, reflecting the market average, is just a backdrop. It helps assess how this business, dependent on the success of partners and R&D budgets, stacks up against the backdrop of overall macroeconomic fluctuations.
